CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Avastin for Cervical Cancer - Details

Project Number PC0045-000
Brand Name Avastin
Generic Name Bevacizumab
Strength 25mg/mL
Tumour Type Gynecology
Indication Cervical Cancer
Funding Request In combination with chemotherapy for the treatment of patients with persistent, recurrent, or metastatic carcinoma of the cervix
Review Status Complete
Pre Noc Submission Yes
NOC Date N/A
Manufacturer Hoffmann-La Roche Limited
Sponsor Hoffmann-La Roche Limited
Submission Date October 27, 2014
Submission Deemed Complete November 3, 2014
Submission Type Initial
Prioritization Requested Requested and Not Granted
Stakeholder Input Deadline ‡ November 10, 2014
Check-point meeting December 16, 2014
pERC Meeting February 19, 2015
Initial Recommendation Issued March 5, 2015
Feedback Deadline ‡ March 19, 2015
Final Recommendation Issued March 23, 2015
Notification to Implement Issued April 8, 2015
Therapeutic Area Cervical Cancer
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.